Prevnar Market Report 2026

Prevnar Market Overview

• The Prevnar market growth in the historic period has been driven by implementation of national immunization programs, increasing incidence of pneumococcal diseases • Market expansion is supported by expansion of higher-valency pneumococcal vaccines, rising focus on adult immunization schedules • Growth Driver: Rising Pneumococcal Disease Prevalence Boosts Demand For Market • Market Trend: FDA Approval Of PREVNAR 20 Fuels Market Expansion • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prevnar Market?

Prevnar is a series of vaccines developed to protect against pneumococcal infections caused by the bacterium streptococcus pneumoniae. These infections can lead to serious diseases such as pneumonia, meningitis, sepsis, and ear infections, particularly in vulnerable populations such as infants, the elderly, and those with compromised immune systems. Prevnar vaccines use a method called conjugate technology, which links polysaccharides to a protein. The main formulation types of prevnar are prevnar 13 and prevnar 20. Prevnar 13 vaccine targets 13 types of pneumococcal bacteria and is widely used for immunizing children and adults against serious infections like pneumonia and meningitis. The indications are pneumonia, meningitis, sepsis, and others, and distribution channels include distribution partner companies, non-governmental organizations, and government authorities. It is used by various end users, such as pediatric, geriatric, and adult.

What Is The Prevnar Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of higher-valency pneumococcal vaccines, rising focus on adult immunization schedules, increasing government vaccine procurement, growth of preventive healthcare investments, expanding vaccine access in emerging economies. Major trends in the forecast period include expansion of pneumococcal vaccination programs, rising adoption of conjugate vaccine technologies, growing focus on adult and geriatric immunization, enhanced cold-chain vaccine distribution systems, increasing public health immunization coverage.

Global Prevnar Market Segmentation

1) By Formulation: Prevnar 13, Prevnar 20 2) By Indications: Pneumonia, Meningitis, Sepsis, Other Indications 3) By Distribution Channel: Distribution Partner Companies, Non-Governmental Organizations, Government Authorities 4) By End Users: Pediatric, Geriatric, Adult

What Is The Driver Of The Prevnar Market?

The increasing prevalence of pneumococcal diseases is expected to propel the prevnar market going forward. Pneumococcal diseases are infections caused by Streptococcus pneumoniae, ranging from mild conditions such as sinusitis and otitis media to severe illnesses such as pneumonia, meningitis, and sepsis. The prevalence of pneumococcal diseases is rising due to factors such as increasing antibiotic resistance, aging populations with weakened immune systems, and low vaccination coverage. Prevnar is a pneumococcal vaccine used to prevent infections caused by streptococcus pneumoniae, including pneumonia, meningitis, and bloodstream infections, by stimulating the immune system to protect against several pneumococcal strains. For instance, in May 2024, according to Statens Serum Institut, a Denmark-based medical laboratory, the incidence of invasive pneumococcal disease in 2022 accounted for 553 cases, which reached 622 cases in 2023. Therefore, the increasing prevalence of pneumococcal diseases drives the Prevnar industry.

Key Players In The Global Prevnar Market

Major companies operating in the prevnar market are Pfizer Inc.

Global Prevnar Market Trends and Insights

Major companies operating in the prevnar market are focusing on developing innovative solutions, such as next-generation pneumococcal conjugate vaccines, to meet the rising demand for broader serotype protection, enhanced pediatric immunization, and strengthened prevention of invasive pneumococcal disease. Pneumococcal conjugate vaccines use purified capsular polysaccharides chemically linked to a carrier protein, enabling a stronger and longer-lasting immune response compared with older polysaccharide-only vaccines, while expanding coverage against more pneumococcal serotypes. For instance, in April 2023, Pfizer Inc., a US-based pharmaceutical industry company, received the FDA approval for PREVNAR 20 (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes covered by the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through 5 years of age caused by the original seven serotype conjugates contained in PREVNAR.

What Are Latest Mergers And Acquisitions In The Prevnar Market?

In November 2023, Pfizer Inc., a US-based pharmaceutical company, partnered with Beijing Keyoceanmed Pharmaceutical Co., Ltd. for the distribution and promotion of Prevenar 13 in mainland China. The partnership with Beijing Keyoceanmed aims to leverage Keyocean's capabilities in warehousing, distribution, and supply chain management to ensure wider access to Prevenar 13 across China. Beijing Keyoceanmed Pharmaceutical Co. Ltd. is a China-based pharmaceutical company focused on the production of innovative drugs.

Regional Insights

North America was the largest region in the prevnar market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Prevnar Market?

The prevnar market consists of sales of prevnar 13, prevnar 20, and prevnar 7. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prevnar Market Report 2026?

The prevnar market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prevnar industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.